1. Home
  2. FTFT vs SILO Comparison

FTFT vs SILO Comparison

Compare FTFT & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Future FinTech Group Inc.

FTFT

Future FinTech Group Inc.

HOLD

Current Price

$1.16

Market Cap

6.2M

ML Signal

HOLD

Logo Silo Pharma Inc.

SILO

Silo Pharma Inc.

HOLD

Current Price

$0.41

Market Cap

7.2M

ML Signal

HOLD

Company Overview

Basic Information
Metric
FTFT
SILO
Founded
N/A
2010
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Business Services
Apparel
Sector
Consumer Discretionary
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
6.2M
7.2M
IPO Year
2008
2011

Fundamental Metrics

Financial Performance
Metric
FTFT
SILO
Price
$1.16
$0.41
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
233.8K
1.4M
Earning Date
05-19-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.98
EPS
N/A
N/A
Revenue
$3,829,805.00
$72,102.00
Revenue This Year
N/A
$1.86
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
77.46
N/A
52 Week Low
$0.56
$0.22
52 Week High
$4.03
$1.01

Technical Indicators

Market Signals
Indicator
FTFT
SILO
Relative Strength Index (RSI) 41.98 43.78
Support Level $0.94 $0.33
Resistance Level $1.32 $0.42
Average True Range (ATR) 0.16 0.03
MACD -0.04 -0.01
Stochastic Oscillator 9.97 17.62

Price Performance

Historical Comparison
FTFT
SILO

About FTFT Future FinTech Group Inc.

Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The company's reportable segments include asset management services, supply chain financing and trading, and others.

About SILO Silo Pharma Inc.

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.

Share on Social Networks: